New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive ...

Alzheimer’s is a multifaceted disease ... form. Myriad factors—genetics, environment, cardiovascular health, metabolism, and ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

“Altered CNS Cu homeostasis has also been linked to more common neurodegenerative diseases ... pointed to MBLAC1 as a risk factor for a particular form of Alzheimer’s disease (AD), one accompanied by ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

Carrying excess fat in your arms and belly might put you at higher risk for Alzheimer’s disease and Parkinson’s disease, ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

Certain rare genetic variants tied to Parkinson’s and other diseases raise the risk of developing ALS by more than three times, per a study.